# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Chronic Myelomonocytic Leukemia

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 80 results.
Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Status: Recruiting
Last Changed: Mar 19, 2018
First Received: Sep 13, 2017
Disease(s): Chronic Myelomonocytic Leukemia
Locations: CHU de Nice, Nice, France
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Status: Recruiting
Last Changed: Jan 02, 2020
First Received: Oct 29, 2018
Disease(s): Chronic Myelomonocytic Leukemia, Leukemia
Intervention(s): Ruxolitinib
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Oct 16, 2019
First Received: Jun 21, 2016
Disease(s): Leukemia, Myelomonocytic, Chronic
Intervention(s): Tipifarnib
Locations: Mayo Clinic Arizona, Scottsdale, Arizona, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States
Johns Hopkins University, Baltimore, Maryland, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
... and 4 other locations.
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Status: Not yet recruiting
Last Changed: Feb 12, 2020
First Received: Feb 12, 2020
Disease(s): Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Intervention(s): MBG453, Azacitidine, Placebo
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Status: Recruiting
Last Changed: Jul 08, 2019
First Received: Oct 17, 2016
Disease(s): Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Intervention(s): Atezolizumab, Guadecitabine
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Temple University Hospital, Philadelphia, Pennsylvania, United States
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Status: Not yet recruiting
Last Changed: Feb 28, 2020
First Received: Feb 11, 2020
Disease(s): Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Intervention(s): Azacitidine, Cusatuzumab
Locations: Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky, United States
Tulane University School of Medicine, New Orleans, Louisiana, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Weill Cornell Medicine, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
... and 84 other locations.
Tagraxofusp (SL-401) in Patients With CMML or MF
Status: Recruiting
Last Changed: Jan 18, 2020
First Received: Oct 20, 2014
Disease(s): Myelofibrosis, Chronic Myelomonocytic Leukemia
Intervention(s): SL-401
Locations: City of Hope, Duarte, California, United States
University of California, Los Angeles, Los Angeles, California, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 6 other locations.
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Recruiting
Last Changed: Nov 15, 2019
First Received: Aug 31, 2017
Disease(s): Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Intervention(s): Azacitidine, Pevonedistat
Locations: Southern Cancer Center, Daphne, Alabama, United States
Southern Cancer Center, Mobile, Alabama, United States
Southern Cancer Center, Mobile, Alabama, United States
Southeastern Regional Medical Center - CTCA - PPDS, Goodyear, Arizona, United States
Arizona Oncology Associates (Orange HOPE) - USOR, Tucson, Arizona, United States
... and 238 other locations.
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Status: Recruiting
Last Changed: Sep 25, 2019
First Received: Sep 14, 2005
Disease(s): Juvenile Myelomonocytic Leukemia
Intervention(s): Stem Cell Transplant, Preparative Regimen
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Status: Not yet recruiting
Last Changed: Jan 23, 2020
First Received: Jan 23, 2020
Disease(s): Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Intervention(s): Azacitidine, Canakinumab
Locations: M D Anderson Cancer Center, Houston, Texas, United States